Poherdy is the first FDA-approved interchangeable biosimilar to Perjeta for HER2-positive breast cancer, potentially expanding access and reducing costs. Approved for use in combination with ...
The EMA’s recommendation follows evidence that the targeted therapy improves progression-free survival in patients whose ...
FDA approves 1st biosimilar to Perjeta, Poherdy, for HER2-positive breast cancer treatment, enabling pharmacy-level substitution under state law.
So, I think more to come on how first line selection might evolve in the next few years depending on results from other ...
The agreement with EirGenix grants Sandoz exclusive rights to commercialize proposed biosimilar of pertuzumab for treatment ...
As Roche works to switch certain patients with breast cancer over to a fixed-dose combination of two medicines, its ...
Pertuzumab-dpzb is now considered an interchangeable biosimilar to pertuzumab as part of treatment combinations in multiple ...
Innovation has been the backbone of progress across any major public health disease – whether it’s HIV, cancer or ophthalmology.
EirGenix inks licensing agreement with Sandoz AG for commercialization of its independently developed breast cancer biosimilar, EG1206A: Taipei Friday, November 14, 2025, 16:00 Hr ...
Sometimes big breakthroughs in science come from very small changes, curiosity, and more than a little luck. A new study from ...
The FDA has approved a biosimilar of pertuzumab which is indicated for multiple breast cancer settings. The FDA has approved ...
The U.S. Food and Drug Administration (FDA) approved Poherdy (pertuzumab-dpzb) as the first interchangeable biosimilar to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback